HR2450Referred to Committee

Prescription Drug Transparency and Affordability Act

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-03-27
Introduced
3
Cosponsors
HR
ⓘ
Type

Sponsor

Kristen McDonald Rivet
Kristen McDonald Rivet
Democrat · MI · Representative
Votes with party: 92.1% (657 recorded votes)

Full profile: /officials/M001237

Source: Congress.gov · FEC

Cosponsors (3)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

2025-03-27

Source: Congress.gov

Committee Activity

Currently in

Previously

Plain-English Summary

Prescription Drug Transparency and Affordability Act This bill requires pharmacy benefit managers (PBMs) to report, at least once every six months, prescription drug pricing, payment, and utilization data to the health insurance plans for which the PBM provides services. Specifically, a PBM contracted to provide services to an employer or sponsor offering a large group health insurance plan (i.e., a plan with at least 100 employees or participants) must report to the plan certain information for prescription drug claims under the plan. This includes, for each drug, the difference between the compensation paid by the plan to the PBM and the compensation paid by the PBM to the pharmacy. Further, for each therapeutic class of drugs under the plan, a PBM must report (1) the total amount it received in rebates, fees, and discounts; and (2) the net spending for each class after such rebates, fees, and discounts. Each PBM also must report certain information about (1) drugs for which total spending exceeded $10,000; and (2) drugs dispensed through pharmacies affiliated with the plan or PBM, such as the percentage of prescriptions dispensed by such affiliates. Finally, a PBM providing services to any group health insurance plan must provide the plan with a summary document that includes similar information for prescription drug claims under the plan, as determined by the Department of Health and Human Services. Plans must also make certain aggregate summary information available to plan participants. PBMs and plans that violate these requirements are subject to civil penalties.

Plain-English rewrite of the Congressional Research Service summary published on Congress.gov. Cached and reviewed.

Subjects

Health
Full bill text is not yet cached locally.
Open text viewRead on Congress.gov

Related legislation

Bills by the same sponsor or covering overlapping subjects.